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Abstract The Ca2+-calmodulin dependent protein phosphatase, 
calcineurin, is thought o mediate the action of the two immuno- 
suppressants, cyclosporin A (CsA) and FKS06. Calcineurin from 
all species consists of a catalytic A subunit and a regulatory 
peptide B, which plays an essential role in catalysis. The enzy- 
matic function is probably also regulated by an autoinhibitory 
domain (AID) present in the catalytic subunit. We have used the 
yeast two-hybrid system to show that the putative AID of the 
yeast catalytic subunit Cnal binds only to truncated Cnal, devoid 
of AID. Although deletion of the genes encoding the yeast cata- 
lytic subunits of calcineurin (CNA1 and CNA2) maintain the 
interaction, absence of the regulatory subunit Cnbl prevents bind- 
ing. Interestingly, both CsA and FK506 disrupt this interaction, 
whereas binding of Cnal to calmodulin remains unaffected. This 
indicates that a simple cellular system, developed in yeast, could 
provide further insight into an understanding of calcineurin inhibi- 
tion. 
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I. Introduction 
The immunosuppressive drugs, cyclosporin A (CsA) and 
FK506, exert their major therapeutic effect by inhibiting T cell 
activation. CsA is widely used for prevention of graft rejection 
after organ or bone marrow transplantation. The more recently 
discovered FK506, which is 10- to 100-times as potent as CsA, 
can effectively address imilar problems and has shown great 
promise in early clinical trials [1]. 
CsA is a cyclic undecapeptide whereas FK506 is a macrolide 
[1,2]. Despite their structural differences, the two drugs have 
almost indistinguishable effects in the cell. The immunosup- 
pressants cause the down-regulation f certain cytokine genes, 
which is ascribed to the drugs' capacity to interfere in a Ca 2÷- 
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sensitive T cell signal transduction pathway. Interleukin-2 is 
one of the genes the transcription activation of which is severely 
compromised in the presence of CsA or FK506 [1,2]. 
Recent findings indicate that CsA and FK506 act in the cell 
by inhibiting the protein phosphatase, calcineurin [1-3]. It has 
been proposed that the two drugs target calcineurin for inhibi- 
tion only after they are bound to their respective cytosolic 
receptors, cyclophilin or FK506 binding protein (FKBP) [4]. 
The ever- growing family of cyclophilins and the FKBPs are 
collectively known as the immunophilins. Not only do the im- 
munophilins bind an immunosuppressant, they also share the 
property of catalyzing the isomerization of a cis prolyl moiety 
in a peptide bond to the trans form [3]. 
Calcineurin is the only known protein phosphatase that is 
regulated specifically by Ca 2+ and calmodulin [5]. The cal- 
cineurin holoenzyme purified from mammalian cells is a heter- 
odimer consisting of a large catalytic (A) subunit (~ 59 kDa) and 
a small regulatory B subunit (-19 kDa) [1,5]. The A subunit 
binds calmodulin whereas the B subunit attaches to four mole- 
cules of Ca 2÷. Calcineurin is incapable of functioning as a phos- 
phatase in vitro when calmodulin or the B subunit is absent. 
Although the sequences of the B subunit and calmodulin are 
related, neither of the two proteins can complement the other's 
absence [6]. In the presence of Ca 2÷, calmodulin and the B 
subunit, the catalytic activity of the calcineurin holoenzyme is
completely inhibited by a synthetic peptide which corresponds 
to a region in the C- terminus of the A subunit [7,8]. This 
suggests that the catalytic A subunit contains an autoinhibitory 
domain (AID) [7]. 
The budding yeast Saccharomyces cerevisiae ncodes pro- 
teins with properties imilar to the mammalian A and B sub- 
units of calcineurin. In fact, yeast cells possess two genes, 
CNA1 and CNA2, homologous to the mammalian A subunit 
[9,10]. Both the Cnal and Cna2 proteins contain regions which 
have similarity to the putative AID sequence of the mammalian 
enzyme [9]. The B subunit in yeast, which is also conserved 
amongst different species, is encoded by the CNB1 gene [11,12]. 
Inhibition of catalytic activity of an enzyme by an autoinhib- 
itory peptide implies physical association of AID with the ac- 
tive site of the enzyme. We have investigated whether AID of 
Cnalp would interact with the catalytic part of the protein in 
a yeast two-hybrid system [13,14]. In this communication it is 
shown that the two regions bind to each other when a func- 
tional Cnbl protein is present in the cell. Surprisingly, the 
specific interaction between AID and the catalytic domain is 
prevented by CsA and FK506. This opens up a unique possibil- 
ity of identifying the natural igands which specifically affect 
calcineurin activity in the cell. 
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2. Materials and methods 
2.1. Subcloning of yeast CNA1 and CNB1 gene fragments inthe plasmid, 
pTM9, a vector used for integration of ACE1N fusions 
Plasmid pTM9 [14] is a yeast integrating vector (containing the 
S. cerevisiae TRP1 sequence as a selectable marker) which encodes the 
entire promoter of the A CE1 gene and the segment encoding the DNA- 
binding domain of the yeast ranscription activator Ace l (i.e. Ace lN) 
[14]. The 3' end of the ACE1N sequence contains two extra nucleotides 
(GC) just prior to the BglII site, which is used for cloning genes contig- 
uous to the ACE1N fragment. 
Two BglII-HindIII fragments of the S. cerevisiae CNA1 gene, the 
complete coding sequence (1659 bp) and a truncated version CNAIA 
(1516 bp, devoid of AID and sequences C-terminal to AID) [9], were 
amplified by the polymerase chain reaction (PCR) [15] using genomic 
DNA from the wild-type yeast strain $288C (American Type Culture 
Collection #26108) as template. The primers used were 5'-ATAGAT- 
CTAATGTCGAAAGACTTGAATT-3' (primer 1) and 5'-ATAAGC- 
TTTCACAGTTGTGGCTTTTTCTCC-3' (primer 2), for CNA1, and 
primer 1 and 5'-ATAAGCTTCTACAAACCTTCAGTCCCACGA-Y 
for CNA1A. 
The BglII-HindIII fragment of CNA1 or CNA1A and a HindlII 
SacI transcription terminator f agment of the yeast PH05 gene (a 377 
bp segment downstream of the stop codon) [16] were subcloned into 
pTM9 [14], and completely digested with Bgl[I and SacI. The resulting 
plasmids were named pMH6 and pMH7. The gene inserts in the plas- 
mids were confirmed by sequencing. 
The coding sequence of CNB1 (435 bp) [11,12] was isolated as a 
BgllI-EcoRI fragment by PCR, as detailed above, using the primers 
5'-ATAGATCTCATGAAATTAGATAGAGATAG-Y and 5'-ATG- 
AATTCTTACACATCGTATTGCAATG-Y. The BglII-EcoRI frag- 
ment and an EcoRI-SaeI SUC2 transcription terminator (SUC2t) frag- 
ment (a 300 bp segment downstream of the stop codon, isolated by 
PCR) [17] was subcloned into pTM9, digested with BgIII and SacI, for 
construction of plasmid pMH23. 
2.2. Construction of CNA1, CNA2 and CNB disruption plasmids 
The CNA1 and CNA2 genes (promoter and complete coding se- 
quence) [9], were isolated as BamHI-HindlIl fragments by PCR from 
the strain $288C. The primers used were 5'-ATGGATCCCATCGC- 
CTCTTGAAACATG-3' and primer 2 (see section 2.1) for CNA1, and 
5'-ATGGATCCATAGTCTATAATACGTTTG-3' and 5'-ATAAGC- 
TTCTATTTGCTATCATTCTTTGCA-Y for CNA2. 
The BamHI-HindlII fragments were subcloned into pUC19 to ob- 
tain pMH1 and pMH2. Digestion with BstEII removed 130 bp and 653 
bp fragments from the coding sequences of CNA1 and CNA2, respec- 
tively. The sticky ends in the purified large fragments from pMH1, 
pMH2 were flushed with T4 polymerase (Boehringer) and ligated to a 
blunt-ended S. cerevisiae URA3 gene fragment [18] to yield the CNA1 
and CNA2 gene disruption plasmids pMH3 and pMH4, respectively. 
The disruption plasmid for CNB1 was constructed as follows. An 
EcoRI BamHI fragment, containing the promoter and a part of the 
coding sequence, was isolated by PCR from strain $288C, using 
the primers 5'-ATGAATTCGGTAACTCAATGGTGATCAGA-Y 
and 5'-ATGGATCCTTGGACCCACGCCCACTGAAA-Y. A 
BamHI-HindlII fragment containing a part of the coding sequence and 
the transcription terminator was isolated by PCR (using again $288C 
as template) with the two primers 5'-ATGGATCCGACATTGACA- 
AGGACGGTTTC-3' and 5'-ATAAGCTTCTTATTGTTTGTTACA- 
TATAC-3'. The EcoRI-BamHI and the BamHI-HindlII fragments 
from CNB1 were subcloned into pUC19 digested with EcoRI and 
HindlII. The resulting plasmid pUCI91ACNBI has a 34 bp deletion in 
the coding sequence of CNBI. A BgllI URA3 gene fragment [18] was 
subcloned into pUC19/ACNB1 at the unique BamHI site of ACNBI to 
obtain the gene disruption plasmid pKOS. 
2.3. Construction of plasmids that express Acel C-AID, Acel C-( AID) 2 
and A cel C 
The AID sequences were expressed under the control of the yeast 
GAPDH promoter [14]. The plasmid pRH2 was obtained after sub- 
cloning a 393 bp BamHI-EcoRI truncated version [14] of the GAPDH 
promoter downstream of the 275 bp SalI-BamHI fragment from 
pBR322 in pBluescriptlI KS* vector (Stratagene). An EcoRI-SpeI dou- 
ble-stranded DNA linker (encoding 22 amino acids of the nuclear 
localization signal from the SV40 large T antigen) [19], was subcloned 
into pRH2 to yield pRH3. The SalI-SpeI fragment from pRH3 and a 
~ 540 bp XbaI-BgllI fragment, encoding the Ace 1C transcription activa- 
tion domain [14], were ligated to the Sall-BgllI digested pUC19Bgl 
(obtained by modifying the BarnHI site of pUC19 to a BgllI site) to 
yield the plasmid pRHIOC. The -540 bp XbaI-BgllI ACE1 C fragment 
was isolated by PCR from pTM4 [14] using the primers 5'-TATCTA- 
GAGGACGTTCTTTTGGGCCT-3' and 5'-TAAGATCTGCTTGT- 
GAATGTGAGTTATGC-3'. 
The DNA encoding the 42 amino acid peptide, which contains the 
putative AID sequence (see Fig. 1) was isolated as a BgllI-XbaI (~ 130 
bp) fragment by PCR using pMH1 (as a template) and the primers 
5'-ATAGATCTGGGTTTGAATGAAACGCTAA-3' 5'-TATCTAG- 
ACTTTAATATTTTTTCGTA-Y. This fragment bears an extra nu- 
cleotide at the 5' end, following the BgllI site, to make the AID sequence 
in-frame with the ACEIC domain. 
The Sall-Bglll fragment from pRH10C, the BgllI-XbaI AID se- 
quence and a 300 bp XbaI-SacI of the yeast S UC2t (see section 2.1) [17] 
were subcloned into pDP34 [14] to form the plasmid pMH10. This 
encodes a single copy of the AID sequence, which was confirmed by 
sequencing. 
The Sail-BgllI fragment from pRH10C and the BgllI-XbaI AID 
sequence were also subcloned into pUC19. The resulting plasmid was 
named pMH10-19. 
pMH10-19 was digested with XbaI and a double-stranded linker 
encoding the peptide SS-GGGG-SS was ligated unidirectionally. A 
SalI-Xbal fragment from the resulting plasmid pMH10-19-G4 and a 
SpeI SacI AID-SUC2t PCR fragment was subcloned into pDP34. The 
resulting plasmid pMH11 encodes two copies of the AID sequence. This 
has been confirmed by DNA sequencing. 
The SalI-Bglll fragment from pRH10C and a 300 bp BgllI-SacI 
fragment of the yeast S UC2t (see section 2.1) [17] were subcloned into 
pDP34 [14] to yield pRH14C. This plasmid expresses only the AcelC 
sequence and is used as a negative control for the study of protein- 
protein interactions described in this communication. 
2.4. Construction of plasmids that express Acel C-Cmdl 
A Sail- BgllI fragment from pRH10C, a BgllI-SalI yeast calmodulin 
(CMD1) gene fragment (containing the 441 bp coding sequence) [20] 
and a 300 bp SalI SacI SUCt fragment (see section 2.1) [17] were 
subcloned into pDP34 at the Sail, SacI sites. The resulting plasmid is 
referred to as pJC2. The authenticity of the CMD1 fragment, isolated 
by PCR from the strain $288C using the primers 5'-ATAGATCTA- 
ATGTCCTCCAATCTTACCGA-3' 5'-ATGTCGACCTATTTAGA- 
TAACAAAGCAG-3' has been checked by sequencing. 
2.5. Yeast strains and transJbrmations 
The S. cerevisiae strain TFY2 (Matot his ura3-52 trpl-285 acel 
LEU2::YipCL CUP1 r) [14] was used for integration of the 
fusion genes ACEIN-CNA1 (pMH6), ACEIN- CNAIA (pMH7) and 
ACEIN-CNB1 (pMH23) into the yeast genome. In order to disrupt 
CNA1, CNA2 and CNB1 from the yeast genome, the plasmids pMH3, 
pMH4 and pKO8 were utilized. Integrative transformation of the 
ACEIN-CNA1, ACEIN-CNAIA and ACEIN- CNB1 fusions were tar- 
geted to the A CE1 locus. The complete plasmids were thus integrated 
and transformants were selected as TRP1 prototrophs [21]. However, 
after gene replacement a  the CNA1, CNA2 and CNB1 loci, URA3 
prototrophs were selected. To obtain Ura3- mutants, Ura3 ÷ strains 
were transformed with ura3A5 [22] and selected in 5-fluoro-orotic acid 
as described elsewhere [23]. The strain where both CNA1 and CNA2 
genes are disrupted was constructed from a strain which initially carried 
Cnal- and Ura3- mutants. 
For verification of correct integration and gene replacement events, 
PCRs were performed with primers flanking the insertion sites. The 
amplified fragments were analysed by agarose gel-electrophoresis and 
in some cases confirmed by sequencing. The resulting yeast strains, 
bearing the three integrations, are referred to as yMH6 (ACEIN- 
CNA1), yMH7 (ACEIN-CNA1A) and yMH23 (ACEIN-CNB1). The 
two strains with gene disruptions have been named TFY2cnalcna2 
(bearing Cnal- and Cna2- mutants) and TFY2cnbl (which harbors 
only a deletion in CNB1). 
For transformation f the 2-micron based plasmids (i.e. the pDP34 
derivatives) [14], which encode hybrid genes consisting of A CE1 C and 
the gene of interest, the yeast strains yMH6, yMH7 and yMH23 were 
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used as hosts. All pDP34 derivatives contain the URA3 gene [18] as the 
selectable marker for yeast. To substantiate hat a plasmid was still 
maintained in the yeast cell, total DNA from yeast was isolated [24] and 
transformed into E. coli (see below). The DNA derived from the trans- 
formants were subjected to restriction enzyme analysis and sequencing 
[24]. 
All transformations were performed via electroporation [14,24] using 
the Bio-Rad gene pulser. The yeast ransformants u ed in this study are 
described in Table 1. 
2.6. Recombinant DNA techniques 
Manipulation of DNA was carried out by using standard procedures 
[24]. E. coli HB101 was used for the construction and propagation of 
plasmids. PCR was performed using Pfu (Stratagene) or Vent (Bio- 
Labs) DNA polymerases. Double-stranded DNA was sequenced by the 
dideoxynucleotide chain-termination method, using the Applied Bio- 
Systems 370A automated DNA sequencer. 
2. 7. ~-Galactosidase assay and induction of  metallothionein expression 
The assays were performed on yeast strains exactly in the way de- 
scribed previously [14]. All strains are TFY2 derivatives and are highly 
sensitive to Cu 2+. TFY2 bears a CUPI- lacZ fusion at the LEU2 locus 
[14]. 
3. Results and discussion 
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Fig. t. The catalytic subunit A of calcineurin. The active site possibly 
interacts with AID in the inactive conformation (a). Ca 2÷, calmodulin 
and the regulatory subunit B transforms it to an active state (b) [5,6]. 
The autoinhibitory domain (AID), the C-terminal truncated Cna 1 with- 
out its AID sequence (CNA1A) and the calmodulin binding site (CaMbs) 
are depicted. The amino acid sequence of AID from yeast Cnal, used 
in this work, is shown in (a). The region in this peptide which is similar 
to mammalian AID [9] is overlined. 
Two yeast genes, homologous to mammalian calcineurin A 
catalytic subunits, have been identified. They are CNA1 and 
CNA2,  also known as CMP1 and CMP2 [9,10]. Comparison 
of the amino acid sequences of Cna lp  and Cna2p with that of 
a mammalian calcineurin A subunit reveals a presumptive 
calmodulin- binding site and an A ID sequence in both the 
polypeptides [9] (Fig. 1). We have attempted to find out if two 
specific regions of Cnalp  (i.e. A ID and the catalytic domain of 
one of the two A subunits present in yeast) interact with one 
another, when in trans. 
There are a variety of in vitro methods with which interac- 
tions between proteins can be studied [14]. The yeast two- 
hybrid system [13,14] provides a convenient way in which the 
possible association between a peptide and a protein can be 
examined in a cellular environment. The system depends on 
reconstitution of a transcription factor from its two essential 
components, the DNA-binding domain and its activating se- 
quence. The transcription factor, used in our experiments, is the 
yeast Acel protein, which activates transcription from the 
CUP1 operon in the presence of divalent copper [14]. The 
DNA-binding domain of Acel is referred to as Ace lN  and the 
activating sequence is known as AcelC.  When expressed as 
separate domains, the two regions are non-functional. 
In our two-hybrid approach [14], two sets of fusion proteins 
are generated, each consisting of one of the two domains of 
Acel.  In the fusions, the domains are attached to the two 
unique proteins which are being tested for their ability to bind 
to each other. Only when the individual proteins interact can 
Acel be functional again. Depending on the strength of the 
protein-protein i teractions, the activation of gene transcrip- 
tion would vary. In order to study the formation of a functional 
transcriptional ctivator, the activation of two genes (the yeast 
CUP1 and the E. coil lacZ), are monitored in the same cell. 
While CUP1 encodes metallothionein, a strong chelator of cop- 
per, the lacZ gene expresses the fl-galactosidase enzyme. CUP1 
gene expression is determined by the levels of toxic copper 
which the yeast cells can endure during growth [14]. The 
fl-galactosidase expression is measured colorometrically. 
The complete CNA1 gene and a deletion mutant (CNA1A) ,  
Table 1 
Interaction between proteins X and Y (encoded by the gene fusions ACEIN-X and ACEIC-Y) in the yeast wo-hybrid system 
Strain Strain::ACE1N-X fusion Transformed with plasmid Plasmids bearing ACE1C or 
(integrated in the genome) A CE1 C-Y fusion 
yMH6 TFY2: :A CE1N-CNA1 pMH 10 A CE1 C-AID 
yMH6 TFY2::ACE1N-CNA1 pMH11 ACE1C-(AID)2 
yMH6 TFY2::A CEI N-CNA1 pRH 14C ~ A CE1 C 
yMH7 TFY2::A CEI N-CAN1A pMH 10 A CE1 C-AID 
yMH7 TFY2::A CEI N- CNAI A pMH 11 A CE1 C- (AID)2 
yMH7 TFY2::A CE1N-CNAIA pRH14C" A CEI C 
yMH6 TFY2: :A CE1N-CNA1 pJC2 A CE1 C-CMD1 
yMH7 TFY2::A CEIN-CNAIA pJC2 A CE1 C- CMD1 
yMH23 TFY2::A CEI N-CNB1 pJC2 A CE1 C- C MD1 
yMH23 TFY2::A CEI N-CNB1 pRH 14C ~ A CE1 C 
TFY  2cnal cna2 T FY  2cnal cna2: A CE1 N- CNA 1A p M H 11 A CE1 C- (A ID ) 2 
TFY2cnal  cna2 TFY2cnal  cna2::A CE1 N- CNA 1A pRH 14C" A CE1 C 
TFY2cnbl  TFY2cnbl::A CEIN-CNAIA pMH 11 A CEIC- (A1D): 
TFY  2cnb l TFY  2cnb l ::A CEI N-CNA I A pRH 14C" A CE1 C 
aThe plasmid pRH14C was used as a negative control in all experiments where CUP1 and lacZ transcription activation was monitored, pRH14C 
expresses only the transcription activation domain of Acel (i.e. AcelC). 
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Fig. 2. Interaction between yeast calcineurin A subunit (Cnal or 
CnalA) and the autoinhibitory peptide AID (from Cnal), in the yeast 
2-hybrid sytem. (A) Induction of metallothionein expression. Equal 
numbers of cells were spotted onto SD plates containing (I) no CuSO4 
and (II) 150 pM CuSO4 (CuSO4" 5H20; Fluka). Columns 1 3, yMH7 
expressing AcelN-CnalA from the genome; columns 4-6, yMH6 ex- 
pressing AcelN-Cnal from the genome. The strains (see Table 1) are 
transformed with the plasmids pMH 10 (Ace 1 C-AID), pMH 11 (Ace 1C- 
(AID)z) and pRH14C (AcelC). (B) Induction of CuZ+-dependent 
fl-galactosidase expression [14]. Copper concentrations are that of 
CuSO45HzO. Data are expresssed as means_+ S.D. devia- 
tions from at least hree independent transformants. 
which lacks the autoinhibitory domain (see section 2) [9], were 
linked to the DNA-binding domain of ACE1 (i.e. ACE1N). For 
expression, the hybrid genes (ACE1N-CNA1 and ACE1N-  
CNA1A) are integrated into the genome of the yeast TFY2 (see 
section 2 and Table 1) [14]. The genome xpresses ingle copies 
of the fusion proteins. The AcelC-AID hybrid proteins were 
expressed from the 2-micron, multi-copy plasmid pDP34 [14]. 
Two different plasmids were constructed, one containing a sin- 
gle AID sequence and the other which encoded two AID ele- 
ments. The two elements of AID were separated by DNA 
encoding a four-glycine spacer (see section 2) which could make 
the two domains structurally independent of each other. 
Fig. 2 depicts the interaction between CnalA and AID se- 
quences. The observed strength of interactions is probably de- 
pendent on the copies of AID sequences expressed. It should 
be noted that we have been unable to show any interaction 
between the complete Cnal and the autoinhibitory peptides. It
is very likely that the active site of Cnal, which binds the 
autoinhibitory peptide, is concealed when AID is still co- 
valently attached to the calcineurin A subunit (see Fig. 1). 
One could reasonably question the relevance of these interac- 
tions. In order to prove that the approach was valid, an attempt 
was made to establish an interaction between either Cnal or 
CnalA and one of the yeast calmodulins (viz. Cmdl) [20]. In 
parallel, we tried to create an interaction between Cmdl and 
the regulatory B subunit (Cnbl) [11, 2] of yeast calcineurin. We 
have been able to substantiate published reports [5,25] which 
propose that calmodulin binds the catalytic A subunit and not 
the regulatory B polypeptide (Fig. 3). It seems that interaction 
of Cmdl and CnalA is relatively strong compared with its 
binding to Cnal. This might indicate that the site where Cmdl 
binds Cnal is probably completely unmasked with the removal 
of AID sequence (see Fig. 1). 
It could be well imagined that, in the cell, AID normally 
covers the active site of calcineurin and prevents further catal- 
ysis by the enzyme. Only under specific conditions i an AID 
sequence thought o be displaced from the catalytic site of an 
enzyme [7,26,27]. The immunosuppressants CsA and FK506 
inhibit he active phosphatase calcineurin after association with 
the immunophilins [1,2]. It is possible that the drugs and the 
autoinhibitory peptide target an identical site in the enzyme for 
inhibition. If so, then CsA or FK506 should prevent AID occu- 
pying the active site of calcineurin. Indeed, we do find that the 
ability of AID to associate with CnalA, in the two-hybrid sys- 
tem, is dramatically impaired in the presence of CsA and 
FK506 (Fig. 4), and this occurs in a dose-responsive manner 
(Fig. 4B and C). It is noteworty that only after pre-incubation 
of the yeast cells with immunosuppressants is it possible to 
prevent he interaction of AID with CNA1A (see Fig. 4). Ap- 
parently, the drugs do not have any effect once the interaction 
is already established (unpublished observations), hinting that 
AID probably competes with the immunosuppressant-im- 
munophilin complexes for the active site of calcineurin. 
Remarkably, in this yeast system, too, FK506 is at least 
10-times more potent han CsA. It appears that the effect of the 
drugs on this interaction is quite specific since the strength of 
the CnalA-Cmdl interaction is unperturbed at the same con- 
centrations of CsA and FK506 which have an unmistakable 
influence on Cna l~AID binding (Fig. 4D). 
It has been reported that the regulatory B subunit is required 
for the phosphatase activity of calcineurin [25]. If the binding 
of AID to CnalA and the consequent actions of CsA and 
FK506 on this interaction are physiologically relevant for inhi- 
(i) - Cu$O 4 (1I) + CuSO 4 
AcelC-Cmdl Ace lC  AcelC-Cmdl AcelC 




Fig. 3. Interaction of Cnal/Cna 1A/CnB 1 (as Ace 1N fusions) with yeast 
calmodulin Cmdl (as AcelC fusion) (see section 2and Table 1). Induc- 
tion of metallothionein xpression. Equal numbers of cells were spotted 
onto SD plates containing (I) no CuSO4 and (II) 150 pM CuSO4 (as in 
Fig. 2). The expressed fusion proteins AcelN-Cnal (from the genomic 
copy of yMH6), AcelN-Cnbl (from the genomic copy ofyMH23) and 
AcelN-CnalA (from the genomic copy of yMH7) (see Table 1) are 
shown on the left (rows). Columns 1 3, individual integrants are trans- 
formed with the plasmid pJC2 expressing the fusion protein AcelC- 
Cmdl; columns 4-6, individual integrants ransformed with the plas- 
mid which expresses AcelC alone (pRH14C; see Table 1). 
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Fig. 4, Induction of metallothionein and Cu2+-dependent fl-galactosidase expression in the presence/absence of CsA and FK506. Cells were grown 
in SD minimal medium (0.67% yeast nitrogen base without any amino acids, 2% glucose) in the presence of CsA/FK506 at 30°C for 16 h. Cells were 
harvested, washed with SD and the expression for metallothionein and fl-galactosidase (at different concentrations of CuSO4 5H20 ) was conducted 
as described previously [14]. fl-Galactosidase units are obtained from an average of three independent transformants and are depicted as in Fig. 2. 
(A) The binding of (I) Cna 1A to AID and (I I) Cna 1A to Cmdl ,  in the presence/absence of CsA and FK506 as visualized via metallothionein expression. 
(B-D) The effect of CsA and FK506 on the interactions of Cna 1A-AID and Cna 1A-Cmd 1 as monitored by the fl-galactosidase assay. The association 
of CnalA to AID is measured at two different concentrations of CsA (5 and 10 pg/ml) and FK506 (0.5 and 1 pg/ml). 
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Fig. 5. The CnalA-AID interaction i  yeast strains disrupted of the 
regulatory B subunit and catalytic A subunits (see section 2 and 
Table 1). The assay for metallothionein xpression was performed as 
in Fig. 2. The three strains TFY2 (wt), TFY2cnalcna2 (cnalcna2) and 
TFY2cnbl (cnbl), bearing the integrated gene Ace 1N-Cnalzl (see Table 
1), are transformed with the plasmid expressing AcelC-(AID)2 
(pMH 11). As a control, the TFY2cnalcna2 ::A CEIN-CNA1A integrant 
was transformed with pRH 14C (which expresses Ace 1C only). This row 
of transformants are depicted as cnalcna21pRH14C. 
bition ofcalcineurin (presupposing that CnalA is enzymatically 
active in the fusion protein AcelN-CnalA), then inactivation 
of yeast Cnbl  should have a profound effect. We have inquired 
whether, in the absence of CNB1, AID interacts with CnalA 
in the yeast wo-hybrid system. By rendering the genomic opy 
of CNB1 [11,12] non-functional (see section 2), we find that 
AID fails to bind CnalA (Fig. 5). This suggests that a C- 
terminally truncated A subunit, although devoid of its AID 
sequence, still needs a functional B subunit. Interestingly, this 
result seems to parallel earlier evidence that inhibition of the 
catalytic A subunit by cyclophilin-CsA complex requires the 
B subunit [28]. Our observation strengthens the argument that, 
if the B subunit is essential for catalysis, its presence should also 
be necessary for permitting inhibition of the enzyme. 
The pertinence of the result with an inactive B subunit was 
further investigated with a yeast strain which harbors disrupted 
copies of the two catalytic A subunits, Cnal and Cna2 [9]. 
Predictably, the gene disruptions do not prevent binding of the 
two domains, AID and CnalA (Fig. 5). It has also been shown 
that the CnalA-A ID interaction, developed in the strain 
TFY2cnalcna2 (see section 2 and Table 1), can be destroyed 
by CsA and FK506 and that the disruption is also dose-respon- 
sive (data not shown). 
The actual establishment of the interaction between an auto- 
inhibitory peptide and the catalytic domain of an enzyme, by 
the two-hybrid system, could prove to be an interesting side- 
line. We believe that our studies have opened up a new avenue 
in which possible associations of autoinhibitory peptides and 
the corresponding catalytic domains of various protein kinases 
[26,27] would be amenable to further investigations. It has been 
postulated that nature has devised the autoinhibitory peptides 
to be the ideal inhibitors (or substrates) of an enzyme [27]. The 
approach taken in this work could prove valuable in the search 
for agonists and antagonists of any enzyme which contains an 
AID sequence. 
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